Monographie - Tedizolid phosphate

Viimane versioon :
08/05/2024

Tedizolid phosphate

Keemiline struktuur

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Sivextro

Hispaania, Mehhiko, Prantsusmaa, Rumeenia, Saksamaa, Suurbritannia, Sveits, Tšiili

Viited : Tedizolid phosphate

	Tüüp	Avaldamine
3644	Labor	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3753	Labor	Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 2014
3827	Plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3838	Labor	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
4055	Ajaleht	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Ajaleht	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4405	Ajaleht	Ezquer-Garin C, Ferriols-Lisart R, Martinez-López LM, Sangrador-Pelluz C, Nicolás-Picó J, Alós-Almiñana M. Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures Pharmazie 2020 ; 75: 172-176.
4528	Ajaleht	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

Mentions Légales